Jan 6
TransCelerate CEO Janice Chang wants trials to become part of routine care
01/16/2026
Clinical trials are drowning in data. In a TransCelerate/Tufts analysis published in late 2025, phase 3 protocols averaged more than 5.9 million data points, up 67% since 2020.
Read the full article featuring Janice Change from Drug Discovery Trends here.
Related Blog Posts
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. Read the full article featuring Rob DiCicco from Citeline here.
Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders
Interest in digital approaches to clinical protocols has grown steadily as sponsors, solution providers, sites, and regulators explore ways to make study planning and execution more efficient. Read the full article featuring Rob DiCicco from Clinical Leader here.
Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization
To kick off 2026, we spoke with industry experts and leaders in the Bio-IT World community about what they expect and look forward to in the new year. Read the full article featuring Allison Cuff Shimooka from Bio-It World here.